Emile van Ermengem identified the bacterium now called Clostridium botulinum as the source of the poison after a Belgian funeral banquet outbreak.
“in 1897, he discovers the source of the poison, an anaerobic spore-forming bacillus that we call today Clostridium botulinum”
Approved · 0:08:37
Between 1943 and 1947 at Camp Detrick, Carl Lamanna and colleagues produced the first pure crystalline botulinum toxin type A.
“a scientist named Carl Lamina and his team produced the first pure crystalline form of the toxin, botulinum toxin type A”
Approved · 0:09:46
In 1970 President Richard Nixon ordered the US offensive biological weapons stockpiles at Camp Detrick destroyed, with a carve-out for small amounts kept for peaceful purposes.
“Richard Nixon, who's then president, signs an executive order renouncing offensive biological weapons, and orders all stockpiles at Camp Dietrich destroyed.”
Approved · 0:17:09
Cutter Laboratories of Berkeley was one of the early manufacturers licensed in April 1955 to make Jonas Salk's polio vaccine, and some of its lots contained live virus.
“in April of 1955, they were one of the early manufacturers that were licensed to make Jonas Salk's polio vaccine.”
Approved · 0:55:33
The first human study of botulinum toxin for strabismus took place in 1978 at the California Pacific Medical Center in San Francisco.
“The first human study for botulinotoxin happens in 1978 in a single hospital room at the California Pacific Medical Center in San Francisco.”
Approved · 0:32:58
According to the book Death to Beauty, Alan Scott's total cash outlay to take botulinum toxin from monkey studies to first FDA approval was roughly $4 million.
“Scott's total cash outlay to take this biologic from monkey studies all the way to its first approval was roughly $4 million.”
Approved · 0:49:22
In his first year as Allergan CEO, David Pyatt cut overhead headcount by 22% and redirected the savings to the sales force.
“In his freshman year as CEO, Pyatt slashes Allergan's overhead headcount by 22%.”
Approved · 1:52:40
By 2013, therapeutic uses accounted for 54% of Botox sales across about 25 medical conditions.
“by 2013, right towards the end of his term as CEO, Therapeutics was accounting for 54 % of all Botox sales across roughly 25 distinct medical conditions.”
Approved · 1:54:08
In 2006 Allergan bought Inamed for over $3 billion, gaining Juvederm fillers and breast implants for its aesthetics lineup.
“Their foundational purchase in this playbook kicks off in 2006 when they drop over $3 billion to buy Inimed.”
Approved · 1:59:58
Bill Ackman's Pershing Square amassed a 9.7% stake in Allergan worth about $3.2 billion, with Valeant secretly co-funding the effort.
“Bill Ackman's Pershing Square fund had quietly amassed a 9.7 % stake in Allergan, worth about $3.2 billion through a vehicle called PS Fund One.”
Approved · 2:08:48
On November 17, 2014, the sale of Allergan to Actavis was announced at $219 a share, about $66 billion total.
“On November 17, 2014, the sale of Allergan to Actavis was announced at $219 a share, about $66 billion total.”
Approved · 2:17:52
In 2017 Allergan assigned six Restasis patents to the Saint Regis Mohawk Tribe, paying $13.5 million up front and a little over $15 million a year, to try to use tribal sovereign immunity against patent review.
“Allergan assigns them all six key Orange Book Restasis patents and pays them $13.5 million up front and a little over $15 million a year.”
Approved · 2:36:31
On April 4, 2016, the US Treasury issued a temporary regulation targeting serial tax inversions, which undercut the planned Pfizer-Allergan merger.
“On April 4th of 2016, the Treasury stepped in and issued a temporary regulation aimed pretty much squarely of what Allergan was doing.”
Approved · 2:42:15
In August 2016 Allergan sold its global generics business to Teva for $40 billion.
“in August, he takes Allergan's entire global generics business and punts it over to Teva for $40 billion.”
Approved · 2:43:28
According to Alex Kesin, Allergan spent about $60 million around 2011 to get a new potency assay accepted by the FDA to replace the mouse lethality test.
“I remember reading that in 2011, they spent like $60 million to get a new assay for the FDA.”
Approved · 2:59:17
Alan Scott died on December 16, 2021, at age 89.
“Alan Scott passed away on December 16, 2021, at 89 years of age.”
Approved · 3:33:21
Takeda acquired Millennium Pharmaceuticals for $8.8 billion in 2008.
“a year later in 2008, Takeda swoops in to buy Millennium, the company they just left, for $8.8 billion.”
Approved · 0:04:55
Blueprint Medicines spent about $10 million to prescreen kinases against its proprietary inhibitor library.
“spending what was considered a ludicrous amount of money at the time, $10 million to prescreen every kinase against its own proprietary inhibitor library.”
Approved · 0:00:51
Gleevec was developed by chemists at Ciba-Geigy, later Novartis, with Nick Lydon leading the internal program.
“Gleevec was built by chemists at Sibageige, which later became Novartis, with a scientist named Nick Lydon running the program internally”
Approved · 0:17:50
In 2014 Blueprint raised a small round led by Nextech investor Tilo Schroeder with a $2 million check, in a syndicate totaling about $25 million.
“A small additional round finally did come in 2014 with Tilo Schroeder, a young investor at a small firm called Nextech, leading the round with a $2 million check”
Approved · 0:35:17
Roche returned the rights to Gavreto to Blueprint in February 2023 after weak sales.
“So now it's February of 2023. Roche sees that this drug wasn't performing nearly as well as they had hoped. So they end up giving it back to Blueprint.”
Approved · 1:11:12
Surveys published in 2022 found systemic mastocytosis patients waited about six years from first symptom to diagnosis.
“There were these surveys published in 2022 showing that patients with systemic mass cytosis reporting that it took an average of about six years from their first symptom to get an actual diagnosis.”
Approved · 1:13:53
The FDA approved Ayvakit for indolent systemic mastocytosis in May 2023, the first treatment for that group.
“the FDA officially approves Avakit for indolent systemic mastocytosis, the first and only treatment for this much larger group of patients than the aggressive form.”
Approved · 1:24:30
In the Pioneer trial, avapritinib beat placebo by about 6.4 points on the symptom score, below analysts' 7-10 point expectations.
“On the symptom score, which is the measure Wall Street really cared about, avapritinib beat the placebo by about 6.4 points.”
Approved · 1:25:13
Dupixent generated about 14 billion euros for Sanofi in 2024.
“In 2024 alone, DuPixent generated about 14 billion euros for the company.”
Approved · 1:39:15
Sanofi settled the Genzyme CVR lawsuit for about 24 cents on the dollar.
“As it turns out, Sanofi ended up settling years later for 24 cents on the dollar.”
Approved · 1:51:02
Ayvakit's full-year 2025 sales were about $725 million, slightly ahead of Blueprint's pre-deal projection.
“The full year 2025 sales came at around $725 million in revenue, slightly ahead of the projected number Blueprint had set before the deal had even closed.”
Approved · 1:52:43
About 19 Blueprint directors and officers collectively received around $365 million in the Sanofi acquisition.
“The insider group, which is the directors and officers, about 19 people total, collectively clears somewhere around $365 million.”
Approved · 2:01:27
In a November 1995 experiment run in Jim Allison's lab, every mouse given a CTLA-4 blocking antibody was cured of tumors while the control mice died.
“Every mouse that got the antibody was completely cured, no tumors at all, while the entire control group grew sicker and died.”
Approved · 0:07:18
Bristol Myers Squibb's Peter Lindsley's group filed on CTLA-4 in June 1991, about three years before Jim Allison's lab worked out what it did.
“Pierre Lindsley's group at BMS got there in June of 1991, three years ahead of Allison.”
Approved · 0:08:40
Tasuku Honjo's lab discovered the PD-1 gene in 1991, naming it for programmed cell death.
“In 1991, a Japanese researcher named Tasuku Honjo and his lab discovered a gene they named PD-1, which stands for Programmed Death 1.”
Approved · 0:12:03
Organon, the Dutch company where pembrolizumab began, was a subsidiary of the paint maker Akzo Nobel.
“To make things even weirder, Organon was a subsidiary of another company called Axo Nobel,”
Approved · 0:16:51
Schering-Plough acquired Organon in 2007 for $14.4 billion.
“in 2007, Sharing Plow acquires Organon for $14.4 billion in order to enhance their portfolio of late-stage clinical assets.”
Approved · 0:29:59
The FDA granted accelerated approval to pembrolizumab (Keytruda) for advanced melanoma on September 4, 2014.
“On September 4th of 2014, the FDA grants accelerated approval to Pembrolizumab, Keytruda for advanced melanoma.”
Approved · 0:58:23
In BMS's early nivolumab data, none of 17 PD-L1-negative patients responded, while nine of 25 PD-L1-positive patients did.
“Out of 42 patients they evaluated, zero of the 17 PD-L1 negative patients responded, but nine out of the 25 PD-L1 positive patients did.”
Approved · 1:03:43
BMS's all-comers first-line lung cancer trial Checkmate 26 had a hazard ratio of 1.02 and failed, while Merck's enriched Keynote 24 trial succeeded.
“BMS's all comers trial, Checkmate 26, produced a hazard ratio of 1.02. It showed absolutely zero benefit and completely failed.”
Approved · 1:08:18
In 2017 the FDA approved pembrolizumab for any solid tumor with a specific DNA repair defect, the first approval based on a biomarker regardless of tumor origin.
“And in 2017, the FDA approved pembrolizumab for the treatment of any solid tumor with the specific DNA repair defect, regardless of where in the body the cancer originated.”
Approved · 1:16:10
By 2018 there were over 160 PD-1 and PD-L1 drugs in development worldwide.
“There were suddenly over 160 different PD-1 and PD-L1 drugs in the pipeline worldwide.”
Approved · 1:25:29
Gilead spent nearly $5 billion acquiring Forty Seven Inc. for its CD47 drug magrolimab, and the program was later scrapped.
“Gilead spent nearly $5 billion acquiring 47 Inc. to get their flagship CD47 drug, Migrolumab.”
Approved · 1:29:11
After Keynote 24, five-year overall survival for PD-L1-high lung cancer patients on first-line Keytruda was 30%, versus 16% on chemotherapy.
“after Keynote 24, first-line Keytruda monotherapy in PD-L1 high patients, the five-year overall survival rate is 30 % compared to just 16 % on chemo.”
Approved · 1:34:46